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MicroRNA-409-3p Functions as a Tumor Suppressor in Human Lung Adenocarcinoma by Targeting c-Met
were loaded and electrophoresed on an 8% sodium dodecyl sulfate (SDS) polyacrylamide gel and then electroblotted onto nitrocellulose membrane, blocked by 5% skim milk, and probed with the antibodies to c-Met, phosphorylated c-Met (p-c-Met), cleaved caspase-3 , total caspase-3, cleaved PARP, total PARP, phosphorylated AKT (Ser473), total Akt, Bcl-2, Bax, MMP-2, MMP-9 and GAPDH (Santa Cruz Biotechnology, Santa. Cruz, California, USA), followed by treatment with secondary antibody conjugated to horseradish peroxidase. The proteins were detected by the enhanced chemiluminescence system and exposed to x-ray film. Band density was measured by photoimage analysis using the Quantity one software (Bio-Rad, Hercules, CA, USA), and expressed as the percentage of density of the respective housekeeping GAPDH.
3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
The cell viability was measured by MTT assay (Sigma, USA). In brief, the cells were seeded into five 96-well culture plates with each plate having all four kinds of A549 cells transiently transfected with miR-409-3p mimics (miR-NC mimics) or anti-miR-409-3p (anti-miR-NC) (6-parallel wells/group). On each day, 200 μL MTT (5 mg/mL) was added to each well, and the cells were incubated for at 37°C for additional 4h. Then the reaction was stopped by lysing the cells with 150 μL DMSO for 5 min. Optical densities were determined on a Versamax microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 490 nm.
Colony formation assay
The A549 cells stably transfected with pGCMV/miR-409-3p or pGCMV/miR-NC were trypsinized to single cell suspensions and were seeded 6-well plates at 500/well. After 14 days culture RPMI 1640 medium, the colonies were stained with Giemsa solution and the number of colonies was counted. Each experiment was performed in triplicate.
Flow cytometric analysis of apoptosis
The cells were harvested, washed twice with cold PBS, fixed in ice-cold 70% ethanol, and incubated overnight at -20℃. Then, cells were stained with 40 µg/mL of propidium iodide (PI) for 30 min. The minimum of 1.0×10
6 cells were collected and analyzed by software Cell Quest (Becton Dickinson Co., NJ, USA). The percentage of cells with apoptotic nuclei (% apoptosis) was calculated.
Wound healing assay
The cells were seeded into 24-well tissue culture plates. 48h later, an artificial homogenous wound was created onto the monolayer with a sterile plastic 100 μL micropipette tip. After wounding, the debris was removed by washing the cells with serum-free medium. Migration of cells into the wound was observed at different time points. Cells that migrated into the wounded area or cells with extended protrusion from the border of the wound were visualized and photographed under an inverted microscope. A minimum of five randomly chosen areas were measured and the distance of cell migration to the wound area was determined.
Transwell invasion assay
Transwell invasion assays were performed with 6-well matrigel-coated chambers from BD Biosciences (Bedford, MA, USA). In brief, the cells were seeded into inserts at 05.0×10 3 /insert in serum-free medium and then transferred to wells filled with the culture medium containing 10% FBS as a chemoattractant. After 24h of incubation, non-invading cells on the top of the membrane were removed by scraping. Invaded cells on the bottom of the membrane were fixed, followed by staining with 0.05% crystal violet. The number of invaded cells on the membrane was then counted under a microscope.
Luciferase activity assay
To testify the validation of c-Met as a direct target of miR-409-3p, we performed miRNA target luciferase reporter assay using a pEZX-MT01 target reporter plasmid containing c-Met/3'-UTR (Genecoepia, Rockville, MD). Additionally, we generated mutant c-Met/3'-UTR reporter construct (pEZX-Luc-c-Met/3'-UTR-mut) by site-directed mutagenesis in the putative target site of miR-409-3p in the wild-type c-Met/3'-UTR (pEZX-Luc-c-Met/3'-UTR-wt) using Stratagene QuikChange® Site-Directed Mutagenesis Kit (Stratagene, Heidelberg, Germany). The cells were transiently cotransfected for 24 h with reporter plasmids (200 ng) and 100 nM of miR-409-3p mimics or inhibitor and harvested in reporter lysis buffer. Both firefly luciferase Cellular Physiology and Biochemistry
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and Renilla luciferase activities were measured using the Dual-Luciferase assay kit (Promega, Madison, WI) according to manufacturer's instructions. The luciferase activity normalized against protein concentration was expressed as a ratio of firefly luciferase to Renilla luciferase unit.
Statistical analysis
Statistical analysis was performed with SPSS version 13.0 (SPSS Inc., Chicago, IL). Values are expressed as the mean±SD. The relationship between miR-409-3p expression and clinicopathologic factors was analyzed by Pearson's chi-squared test. Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. Survival data were evaluated using univariate and multivariate Cox regression analyses. The correlation between the miR-409-3p expression level and the protein level of c-Met was evaluated by Spearman's rank correlation coefficients. P<0.05 was considered statistically significant.
Results

MiR-409-3p is downregulated in primary LAD tissues
First, qRT-PCR assay was performed to detect the expression levels of miR-409-3p in 34 pairs of human LAD tissues and their matched adjacent non-cancerous tissues, and the results indicated that miR-409-3p was significantly downregulated in 79.4% (27/34) of the LAD tissues examined in comparison with the matched adjacent non-cancerous tissues from the same group of patients (Fig. 1A) . Also, we detected the expression of miR-409-3p in a normal human bronchial epithelial cell line (HBE) and three LAD cell lines (A549, SPC-A1 and H1299), and showed that the relative expression level of miR-409-3p in LAD cell lines was significantly lower than that in normal human bronchial epithelial cell line (Fig. 1B) . By statistical analyses, it was shown that the miR-409-3p expression levels were significantly lower in the LAD tissues than the matched adjacent non-cancerous tissues (P=0.013; Fig.  1C ). Also, we detected the expression of miR-409-3p in tumors with various pTNM stage, and results showed that miR-409-3p was expressed at relatively high levels in tumors with an early pTNM stage (pI and pII), and significantly downregulated in pIII tumors and further downregulated in pIV tumors (Fig. 1D) . Also, the expression of miR-409-3p in LAD tissues with or without lymph node metastasis was analyzed. Results indicated that the miR-409-3p expression levels were significantly lower in tumors with lymph node metastasis than those without lymph node metastasis (P=0.007; Fig. 1E ). Thus, these data indicated that lower miR-409-3p expression might be involved in LAD development. 
Correlation of miR-409-3p expression with clinicopathologic factors of LAD patients
To further investigate the correlation between miR-409-3p expression and clinicopathologic factors of LAD patient, the levels of miR-409-3p were quantified in another cohort of 84 LAD tissue samples using real-time RT-PCR. After normalization to U6 expression levels, the expression level of miR-409-3p in LAD tissues (mean±SD: 0.236±0.15) was significantly lower than that in adjacent normal tissues (mean±SD:1.353±0.46, P<0.001). The median expression level of miR-409-3p (0.236) was used as a cutoff point to divide all 84 patients into two groups: LAD patients who express miR-409-3p at levels less than the cutoff value were assigned to the low expression group (mean expression value 0.158, n=38), and those with expression above the cutoff value were assigned to the high expression group (mean expression value 0.697, n=46). As shown in Table. 1, statistical analyses indicated that low miR-409-3p expression in LAD was significantly correlated with poor tumor differentiation, advanced pTNM stage and higher incidence of lymph node metastasis (P=0.032, 0.028 and 0.020, respectively). However, there were no statistically significant correlation between miR-409-3p expression and other factors including age, gender, smoking condition, T-primary tumor and cancer-related death (P=0.744, 0.433, 0.071, 0.569 and 0.411, respectively).
MiR-409-3p is an independent prognostic factor for LAD patients
Next, we investigated the correlation of miR-409-3p expression with prognosis of LAD patients. Kaplan-Meier survival curves were plotted according to miR-409-3p expression, pTNM stage and status of lymph node metastasis. As shown in Fig. 2A , LAD patients with low-miR-409-3p expression had a lower recurrence-free survival than those patients with high-miR-409-3p expression (P=0.0008). As shown in Fig. 2B , LAD patients with high-miR-409-3p expression showed a better prognosis than those with low-miR-409-3p expression The r e c u r r e n c efree survival (RFS) probability in LAD patients with high miR-409-3p expression was significantly higher than that in patients with low miR-409-3p. (B) The overall survival (OS) probability in LAD patients with high miR-409-3p expression was significantly higher than that in patients with low miR-409-3p expression. (C) The OS probability in LAD patients with high pTNM stage (pIII+IV) was significantly lower than that in patients with low pTNM stage (pI+II). (D) The OS probability in LAD patients with lymph node metastasis was significantly lower than that in patients without lymph node metastasis. *P<0.05, **P<0.01.
(P=0.0261). The median survival time for the LAD patients with high-miR-409-3p was 52.4 months, and for LAD patients with low-miR-409-3p was 32.4 months. Also, we also found that patients with pTNM stage (pIII+IV) had shorter survival time than those with pTNM stage (pI+II) (P=0.0022; Fig. 2C ). Additionally, LAD patients with lymph node metastasis had a shorter survival time than those with no lymph node metastasis (P=0.0108; Fig. 2D ). The data of univariate and multivariate analyses of factors correlated with prognosis of LAD patient were indicated in Table. 2. By univariate survival analysis, it was observed that tumor differentiation, pTNM stage, and miR-409-3p expression were closely correlated with 5-year OS of LAD patients (P=0.008, 0.016 and 0.006, respectively). Further, multivariate Cox regression analyses showed that status of miR-409-3p, along with pTNM stage, was independent prognostic factors for LAD patients (P=0.038 and 0.026, respectively).
MiR-409-3p inhibits growth and enhances apoptosis in LAD cells
To better understanding the biological functions of miR-409-3p in the development of LAD, we first investigate the effect of miR-409-3p on growth and apoptosis of LAD cells. 48h After LAD cell line (A549) was transfected with miR-409-3p mimics or miR-409-3p inhibitor (anti-miR-409-3p), qRT-PCR was performed to detect the expression of miR-409-3p. As shown in Fig. 3A , compared with control mimics or anti-miR-NC-transfected cells, the expression of miR-409-3p was significantly increased in miR-409-3p mimics-transfected (Fig. 3B) . Colony formation assay showed that the ability of colony formation in A549 cells stably transfected with pGCMV/miR-409-3p was significantly reduced in comparison with that in miR-NC mimics-transfected cells (P<0.01; Fig. 3C ). In addition, transfection of miR-409-3p mimics induced apoptosis (14.56% versus 4.51% in the control group; P<0.01; Fig. 3D ). Furthermore, the expression of cleaved caspase-3 and PARP proteins was significantly upregulated in miR-409-3p mimics-transfected A549 cells compared with miR-NC mimics-transfected cells (Fig. 3E) . Likewise, we also confirmed that upregulation of miR-409-3p could inhibit growth and increase apoptosis in another LAD cell line (SPC-A1) (Fig. 4A-D) . Collectively, miR-409-3p significantly inhibits the growth of LAD cells by promoting caspase-3-dependent apoptosis.
MiR-409-3p inhibits in vitro migration and invasion in LAD cells
Then, we will investigate the effect of miR-409-3p expression on migration and invasion of LAD cells. Wound healing assays showed that the migration of A549 cells was significantly decreased after transfection of miR-409-3p mimics (Fig. 5A) . In contrast, anti-miR-409-3p increased wound healing (Fig. 5B) . Similarly, in Matrigel invasion assays, upregulation of miR-409-3p could significantly reduce invasion of A549 cells (123 versus 412, P<0.01; Fig.  5C ). Likewise, downregulation of miR-409-3p could markedly increase invasion of A549 cells Fig. 5D ). Likewise, we also confirmed that stable transfection of miR-409-3p could reduce migration and invasion in SPC-A1 cell line (Fig. 4E) . These results suggest that miR-409-3p significantly inhibits in vitro migration and invasion of LAD cells.
c-Met is identified as a direct target of miR-409-3p
To investigate the targets of miR-409-3p to elucidate the underlying mechanisms of its effects, we performed miRNA target gene prediction with PicTar, TargetScan and Miranda databases. The c-Met exhibited miR-409-3p-binding sequences in its 3'-UTR regions (Fig.  6A) , and in silico analysis showed 3'-UTR of human c-Met (4912-4978 nt) contains a potential miR-409-3p binding site. To further confirm that the c-Met 3'-UTR is a target for miR-409-3p, we subcloned the fragment of c-Met 3'-UTR harboring the potential binding site into downstream of the pEZX-Luc vector to generate the pEZX-luc-c-Met/3'-UTR-wt vector and mutated the miR-409-3p binding site on c-Met 3'-UTR (c-Met/3'-UTR-mut) and subcloned it into pEZX-luc vector generate the pEZX-luc-c-Met/3'-UTR-mut vector. Those vectors were co-transfected into A549 cells with miR-409-3p mimics (or miR-NC mimics) or anti-miR-409-3p (or anti-miR-NC), and luciferase activity was determined. As shown in Fig. 6B , the luciferase activity was decreased by miR-409-3p mimics (P<0.01) when the wildtype c-Met/3'-UTR was present, and the activity was increased (P<0.05) when miR-409-3p was downregulated. However, the mutations of c-Met/3'-UTR prevented the expression of miR-409-3p from affecting luciferase activity. Next, we analyzed the effect of miR-409-3p expression on the expression of c-Met in LAD cells. As shown in Fig. 6C , transfection of miR-409-3p mimics could lead to the decreased expression of c-Met protein in A549 cells (P<0.05), while transfection of miR-409-3p inhibitor could lead to the increased expression 
shRNA-mediated c-Met downregulation inhibits growth, induce apoptosis, reduce migration and invasion in LAD cells
Previous studies have shown that c-Met (hepatocyte growth factor receptor), a tyrosine kinase receptor for hepatocyte growth factor (HGF), plays an important role in malignant transformation and tumor development by activating mitogenic signaling pathways [16, 17] . To better understand the biological functions of c-Met in LAD, shRNA/c-Met1 or 2 and shRNA/ control vector was stably transfected into A549 cells, respectively. qRT-PCR and Western blot assays confirmed the downregulation of c-Met mRNA and protein induced by shRNA/c-Met1 or shRNA/c-Met2, and shRNA/c-Met2 exhibited the stronger inhibitory effect (Fig. 7A) . Thus, shRNA/c-Met2 was chosen for further functional analyses. Results from MTT assay indicated that siRNA-mediated downregulation of c-Met could significantly inhibit growth of A549 cells and the highest inhibitory rate was 36.6±2.3% at 5 days (P<0.01; Fig. 7B ). Compared with shRNA/control-transfected cells, the apoptotic rate of shRNA/c-Met2-transfected A549 cells was significantly increased by about 22.4% (P<0.01; Fig. 7C ). Meanwhile, silencing of c-Met2 significantly increased the expression of cleaved caspase-3 and PARP proteins in A549 cells (Fig. 7D) . Wound healing and Matrigel invasion assays indicated that shRNA/cMet2 could significantly reduce the capacities of migration and invasion in A549 cells (Fig.  7E and F) . These results suggest that shRNA-mediated downregulation of c-Met can mimic the effect of miR-409-3p upregulation on phenotypes of LAD cells. (Fig. 9A) . Also, both upregulation of miR-409-3p and downregulation of c-Met induced the inhibition of phosphorylated Akt (pAkt) protein expression but had no effects on the expression of total Akt protein in A549 cells (Fig. 9B) . Then, we detect the expression of downstream targets of Akt signaling, including Bcl-2, Bax, MMP-2 and MMP-9. Likewise, we showed that both miRNA-409-3p mimics and shRNA/c-Met2 could inhibit the expression of Bcl-2 protein and increase the expression of Bax protein, which induced the decreased ratio of Bcl-2/Bax (Fig. 9C) . Also, the expression of MMP-2 and MMP-9 proteins was observed to be significantly downregulated in both miR-409-3p mimics and shRNA/c-Met2-transfected cells (Fig. 9D) . Those targets of Akt signaling was correlated with growth and metastasis of LAD cells, so miR-409-3p might affect phenotypes of LAD cells via regulation of those targets. Therefore, it was concluded that miR-409-3p inhibited growth, increased apoptosis and reduced invasion of LAD cells via inactivation of Akt signaling by targeting c-Met.
c-Met is upregulated and inversely correlated with miR-409-3p expression in human LAD tissues
To further examine the role of c-Met in LAD development, c-Met protein was detected in 34 cases of paired non-cancerous tissue (N) and LAD (T) tissue samples by Western blotting assay. The mean level of c-Met protein in LAD tissues was significantly higher than that in non-cancerous tissues (P=0.0054; Fig. 10A and B) . Next, we investigated whether c-Met protein expression was inversely correlated with levels of miR-409-3p in LAD tissues. A total of 34 LAD tissues were analyzed for the expression levels of c-Met and for miR-409-3p expression. A statistically significant inverse correlation was observed between c-Met and miR-409-3p (r= -0.416; P=0.026, Pearson's correlation; Fig. 10C ). Therefore, these data further supported that downregulation of miR-409-3p was inversely correlated with overexpression of c-Met in LAD tissues.
Discussion
Emerging evidence has shown that dysregulation of miRNAs plays critical roles in tumorigenesis and the functions of miRNAs are complicated because they can downregulate numerous target genes including tumor suppressors and oncogenes [19] . Thus, it is necessary to explore their roles in tumor development. In the present study, we showed for the first time that miR-409-3p was significantly downregulated in LAD and an independent prognostic factor for patients. Functional analyses indicated that miR-409-3p could inhibit growth, induce apoptosis and reduce invasion in LAD cells via inactivation of Akt signaling by targeting c-Met. These data indicates that miR-409-3p may be a novel tumor suppressor which plays fundamental roles in lung carcinogenesis.
The pathogenesis of LAD involves multiple factors, including genetic predisposition, epigenetic regulation and environmental interaction [20] . The recent discovery of miRNAs and their epigenetic regulation add further complexity in human diseases and are attached more importance. Recently, correlations of aberrant expression of miRNAs and growth, metastasis and chemo-or radioresistance of LAD are increasingly reported. Kitamura' et al showed that miR-134/487b/655 cluster could regulate TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells [21] . Zhao and his colleagues reported that downregulation of miR-145 might contribute to lung adenocarcinoma cell growth to form brain metastases [22] . Xiang' et al showed that microRNA-98 could sensitize cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2 [23] . Liu and his colleagues reported that microRNA-449a could enhance radiosensitivity in CL1-0 lung adenocarcinoma cells [24] . However, the roles of miR-409-3p in LAD progression remain unclear and need to be further elucidated. First, we analyzed the correlation of miR-409-3p expression with clinicopathologic factors of LAD patients, and showed that the expression of miR-409-3p was closely correlated with tumor differentiation, pTNM stage and lymph node metastasis and poor survival of LAD patients. Further functional analysis indicated that transfection of miR-409-3p mimics could inhibit growth, induce apoptosis and inhibit migration or invasion in LAD cell. These data suggest that miR-409-3p functions as a tumor suppressor in LAD cells. Consistent with our work, other groups have reported that miR-409-3p functions as a tumor suppressor in gastric cancer. Zheng and his colleagues showed that microRNA-409-3p could suppress tumour cell invasion and metastasis by directly targeting radixin in gastric cancers [14] . Also, Li' et al reported that microRNA-409-3p could regulate cell proliferation and apoptosis by targeting PHF10 in gastric cancer [25] . In bladder cancer, microRNA-409-3p is reported to inhibit migration and invasion of bladder cancer cells via targeting c-Met [13] . Moreover, miR-409-3p can inhibit HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin [15] . In this report, we have, for the first time, established the role of miR-409-3p in LAD growth and invasion. Our findings, together with other results, indicated that miR-409-3p might function as a tumor suppressor in human cancers. Interestingly, Nadal and his groups identified a microRNA cluster at 14q32 drives aggressive lung adenocarcinoma, and further confirmed that eleven of 22 miRNAs associated with poor survival were encoded in a large miRNA cluster at 14q32, including 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) [26] . Although it is also originated from the chromosome 14q32 region, it acts as a tumor suppressor in LAD cells. However, little is known about the underlying molecular mechanisms of miR-409-3p in human LAD.
c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including Akt signaling pathway [27] . To date, c-Met has been well-established as playing critical roles in growth, motility, migration and invasion [28, 29] . c-Met has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression [30] . Previous study has reported that activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line [31] . Also, Stabile and his colleagues reported that transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer [32] . Interestingly, it is found that HGF/ c-MET system constitutes an autocrine activation loop in cancer-stromal myofibroblasts and this autocrine system may play a role in invasion and metastasis of lung adenocarcinoma [33] . Subsequent study shows that c-Met is directly downregulated by miR-449a, which inhibits growth and invasion of non-small cell lung cancer cells [34] . As one mRNA can be potentially regulated by multiple miRNAs [35] , whether c-Met can be regulated by other miRNAs in human LAD needs to be further elucidated. In the present study, we confirmed that c-Met was a direct and functional target of miR-409-3p. A negative correlation between miR-409-3p Third, phenotypic analyses from pooled transfectants were performed, and phenotypic separation followed by differential expression analyses of miR409-3p and c-Met expression should be performed.
In conclusion, the present study shows for the first time that miR-409-3p is downregulated in LAD and may be an independent poor prognostic factor for patients. MiR-409-3p possesses the potency to inhibit LAD growth, migration and invasion via regulation of Akt signaling pathway by targeting c-Met. The newly identified miR-409-3p/c-Met axis provides a novel insight into the pathogenesis of LAD, and provides us a wider perspective on LAD intervention and treatment.
